PET/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy

Paco E. Bravo, Aurélio Pinheiro, Takahiro Higuchi, Christoph Rischpler, Jennifer Merrill, Miguel Santaularia-Tomas, M. Roselle Abraham, Richard L. Wahl, Theodore P. Abraham, Frank M. Bengel

Research output: Contribution to journalArticle

Abstract

Patients with obstructive hypertrophic cardiomyopathy (HCM) exhibit elevated left ventricular outflow tract gradients (LVOTGs) and appear to have a worse prognosis than those with nonobstructive HCM. The aim of this study was to evaluate whether patients with obstruction, compared with nonobstructive HCM, demonstrate significant differences in PET parameters of microvascular function. Methods: PET was performed in 33 symptomatic HCM patients at rest and during dipyridamole stress (peak) for the assessment of regional myocardial perfusion (rMP), left ventricular ejection fraction (LVEF), myocardial blood flow (MBF), and myocardial flow reserve (MFR). Myocardial wall thickness and LVOTG were measured with an echocardiogram. Patients were divided into the following 3 groups: nonobstructive (LVOTG <30 mm Hg at rest and after provocation test with amyl nitrite), obstructive (LVOTG > 30 mm Hg at rest and with provocation), and latent HCM (LVOTG <30 at rest but > 30 mm Hg with provocation). Results: Eleven patients were classified as nonobstructive (group 1), 12 as obstructive (group 2), and 10 as latent HCM (group 3). Except for age (42 ± 18 y for group 1, 58 ± 7 y for group 2, and 58 ± 12 y for group 3; P = 0.01), all 3 groups had similar baseline characteristics, including maximal wall thickness (2.3 ± 0.5 cm for group 1, 2.2 ± 0.4 cm for group 2, and 2.1 ± 0.7 cm for group 3; P = 0.7). During peak flow, most patients in groups 1 and 2, but fewer in group 3, exhibited rMP defects (73% for group 1, 100% for group 2, and 40% for group 3; P = 0.007) and a drop in LVEF (73% for group 1, 92% for group 2, and 50% for group 3; P = 0.09). Peak MBF (1.58 ± 0.49 mL/min/g for group 1, 1.72 ± 0.46 mL/min/g for group 2, and 1.97 ± 0.32 mL/min/g for group 3; P = 0.14) and MFR (1.62 ± 0.57 for group 1, 1.90 ± 0.31 for group 2, and 2.27 ± 0.51 for group 3; P = 0.01) were lower in the non-obstructive and higher in the latent HCM group. LVOTGs demonstrated no significant correlation with any flow dynamics. In a multivariate regression analysis, maximal wall thickness was the only significant predictor for reduced peak MBF (β = -0.45, P = 0.003) and MFR (β = -0.63, P = 0.0001). Conclusion: Maximal wall thickness was identified as the strongest predictor of impaired dipyridamole-induced hyperemia and flow reserve in our study, whereas outflow tract obstruction was not an independent determinant.

Original languageEnglish (US)
Pages (from-to)407-414
Number of pages8
JournalJournal of Nuclear Medicine
Volume53
Issue number3
DOIs
StatePublished - Mar 1 2012

Fingerprint

Hypertrophic Cardiomyopathy
Dipyridamole
Stroke Volume
Perfusion
Hyperemia
Multivariate Analysis
Regression Analysis

Keywords

  • Hypertrophic cardiomyopathy
  • Myocardial blood flow
  • Outflow tract obstruction
  • PET

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Bravo, P. E., Pinheiro, A., Higuchi, T., Rischpler, C., Merrill, J., Santaularia-Tomas, M., ... Bengel, F. M. (2012). PET/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy. Journal of Nuclear Medicine, 53(3), 407-414. https://doi.org/10.2967/jnumed.111.096156

PET/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy. / Bravo, Paco E.; Pinheiro, Aurélio; Higuchi, Takahiro; Rischpler, Christoph; Merrill, Jennifer; Santaularia-Tomas, Miguel; Abraham, M. Roselle; Wahl, Richard L.; Abraham, Theodore P.; Bengel, Frank M.

In: Journal of Nuclear Medicine, Vol. 53, No. 3, 01.03.2012, p. 407-414.

Research output: Contribution to journalArticle

Bravo, PE, Pinheiro, A, Higuchi, T, Rischpler, C, Merrill, J, Santaularia-Tomas, M, Abraham, MR, Wahl, RL, Abraham, TP & Bengel, FM 2012, 'PET/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy', Journal of Nuclear Medicine, vol. 53, no. 3, pp. 407-414. https://doi.org/10.2967/jnumed.111.096156
Bravo, Paco E. ; Pinheiro, Aurélio ; Higuchi, Takahiro ; Rischpler, Christoph ; Merrill, Jennifer ; Santaularia-Tomas, Miguel ; Abraham, M. Roselle ; Wahl, Richard L. ; Abraham, Theodore P. ; Bengel, Frank M. / PET/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy. In: Journal of Nuclear Medicine. 2012 ; Vol. 53, No. 3. pp. 407-414.
@article{7c1c213b05b64c9298543218dab545c6,
title = "PET/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy",
abstract = "Patients with obstructive hypertrophic cardiomyopathy (HCM) exhibit elevated left ventricular outflow tract gradients (LVOTGs) and appear to have a worse prognosis than those with nonobstructive HCM. The aim of this study was to evaluate whether patients with obstruction, compared with nonobstructive HCM, demonstrate significant differences in PET parameters of microvascular function. Methods: PET was performed in 33 symptomatic HCM patients at rest and during dipyridamole stress (peak) for the assessment of regional myocardial perfusion (rMP), left ventricular ejection fraction (LVEF), myocardial blood flow (MBF), and myocardial flow reserve (MFR). Myocardial wall thickness and LVOTG were measured with an echocardiogram. Patients were divided into the following 3 groups: nonobstructive (LVOTG <30 mm Hg at rest and after provocation test with amyl nitrite), obstructive (LVOTG > 30 mm Hg at rest and with provocation), and latent HCM (LVOTG <30 at rest but > 30 mm Hg with provocation). Results: Eleven patients were classified as nonobstructive (group 1), 12 as obstructive (group 2), and 10 as latent HCM (group 3). Except for age (42 ± 18 y for group 1, 58 ± 7 y for group 2, and 58 ± 12 y for group 3; P = 0.01), all 3 groups had similar baseline characteristics, including maximal wall thickness (2.3 ± 0.5 cm for group 1, 2.2 ± 0.4 cm for group 2, and 2.1 ± 0.7 cm for group 3; P = 0.7). During peak flow, most patients in groups 1 and 2, but fewer in group 3, exhibited rMP defects (73{\%} for group 1, 100{\%} for group 2, and 40{\%} for group 3; P = 0.007) and a drop in LVEF (73{\%} for group 1, 92{\%} for group 2, and 50{\%} for group 3; P = 0.09). Peak MBF (1.58 ± 0.49 mL/min/g for group 1, 1.72 ± 0.46 mL/min/g for group 2, and 1.97 ± 0.32 mL/min/g for group 3; P = 0.14) and MFR (1.62 ± 0.57 for group 1, 1.90 ± 0.31 for group 2, and 2.27 ± 0.51 for group 3; P = 0.01) were lower in the non-obstructive and higher in the latent HCM group. LVOTGs demonstrated no significant correlation with any flow dynamics. In a multivariate regression analysis, maximal wall thickness was the only significant predictor for reduced peak MBF (β = -0.45, P = 0.003) and MFR (β = -0.63, P = 0.0001). Conclusion: Maximal wall thickness was identified as the strongest predictor of impaired dipyridamole-induced hyperemia and flow reserve in our study, whereas outflow tract obstruction was not an independent determinant.",
keywords = "Hypertrophic cardiomyopathy, Myocardial blood flow, Outflow tract obstruction, PET",
author = "Bravo, {Paco E.} and Aur{\'e}lio Pinheiro and Takahiro Higuchi and Christoph Rischpler and Jennifer Merrill and Miguel Santaularia-Tomas and Abraham, {M. Roselle} and Wahl, {Richard L.} and Abraham, {Theodore P.} and Bengel, {Frank M.}",
year = "2012",
month = "3",
day = "1",
doi = "10.2967/jnumed.111.096156",
language = "English (US)",
volume = "53",
pages = "407--414",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "3",

}

TY - JOUR

T1 - PET/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy

AU - Bravo, Paco E.

AU - Pinheiro, Aurélio

AU - Higuchi, Takahiro

AU - Rischpler, Christoph

AU - Merrill, Jennifer

AU - Santaularia-Tomas, Miguel

AU - Abraham, M. Roselle

AU - Wahl, Richard L.

AU - Abraham, Theodore P.

AU - Bengel, Frank M.

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Patients with obstructive hypertrophic cardiomyopathy (HCM) exhibit elevated left ventricular outflow tract gradients (LVOTGs) and appear to have a worse prognosis than those with nonobstructive HCM. The aim of this study was to evaluate whether patients with obstruction, compared with nonobstructive HCM, demonstrate significant differences in PET parameters of microvascular function. Methods: PET was performed in 33 symptomatic HCM patients at rest and during dipyridamole stress (peak) for the assessment of regional myocardial perfusion (rMP), left ventricular ejection fraction (LVEF), myocardial blood flow (MBF), and myocardial flow reserve (MFR). Myocardial wall thickness and LVOTG were measured with an echocardiogram. Patients were divided into the following 3 groups: nonobstructive (LVOTG <30 mm Hg at rest and after provocation test with amyl nitrite), obstructive (LVOTG > 30 mm Hg at rest and with provocation), and latent HCM (LVOTG <30 at rest but > 30 mm Hg with provocation). Results: Eleven patients were classified as nonobstructive (group 1), 12 as obstructive (group 2), and 10 as latent HCM (group 3). Except for age (42 ± 18 y for group 1, 58 ± 7 y for group 2, and 58 ± 12 y for group 3; P = 0.01), all 3 groups had similar baseline characteristics, including maximal wall thickness (2.3 ± 0.5 cm for group 1, 2.2 ± 0.4 cm for group 2, and 2.1 ± 0.7 cm for group 3; P = 0.7). During peak flow, most patients in groups 1 and 2, but fewer in group 3, exhibited rMP defects (73% for group 1, 100% for group 2, and 40% for group 3; P = 0.007) and a drop in LVEF (73% for group 1, 92% for group 2, and 50% for group 3; P = 0.09). Peak MBF (1.58 ± 0.49 mL/min/g for group 1, 1.72 ± 0.46 mL/min/g for group 2, and 1.97 ± 0.32 mL/min/g for group 3; P = 0.14) and MFR (1.62 ± 0.57 for group 1, 1.90 ± 0.31 for group 2, and 2.27 ± 0.51 for group 3; P = 0.01) were lower in the non-obstructive and higher in the latent HCM group. LVOTGs demonstrated no significant correlation with any flow dynamics. In a multivariate regression analysis, maximal wall thickness was the only significant predictor for reduced peak MBF (β = -0.45, P = 0.003) and MFR (β = -0.63, P = 0.0001). Conclusion: Maximal wall thickness was identified as the strongest predictor of impaired dipyridamole-induced hyperemia and flow reserve in our study, whereas outflow tract obstruction was not an independent determinant.

AB - Patients with obstructive hypertrophic cardiomyopathy (HCM) exhibit elevated left ventricular outflow tract gradients (LVOTGs) and appear to have a worse prognosis than those with nonobstructive HCM. The aim of this study was to evaluate whether patients with obstruction, compared with nonobstructive HCM, demonstrate significant differences in PET parameters of microvascular function. Methods: PET was performed in 33 symptomatic HCM patients at rest and during dipyridamole stress (peak) for the assessment of regional myocardial perfusion (rMP), left ventricular ejection fraction (LVEF), myocardial blood flow (MBF), and myocardial flow reserve (MFR). Myocardial wall thickness and LVOTG were measured with an echocardiogram. Patients were divided into the following 3 groups: nonobstructive (LVOTG <30 mm Hg at rest and after provocation test with amyl nitrite), obstructive (LVOTG > 30 mm Hg at rest and with provocation), and latent HCM (LVOTG <30 at rest but > 30 mm Hg with provocation). Results: Eleven patients were classified as nonobstructive (group 1), 12 as obstructive (group 2), and 10 as latent HCM (group 3). Except for age (42 ± 18 y for group 1, 58 ± 7 y for group 2, and 58 ± 12 y for group 3; P = 0.01), all 3 groups had similar baseline characteristics, including maximal wall thickness (2.3 ± 0.5 cm for group 1, 2.2 ± 0.4 cm for group 2, and 2.1 ± 0.7 cm for group 3; P = 0.7). During peak flow, most patients in groups 1 and 2, but fewer in group 3, exhibited rMP defects (73% for group 1, 100% for group 2, and 40% for group 3; P = 0.007) and a drop in LVEF (73% for group 1, 92% for group 2, and 50% for group 3; P = 0.09). Peak MBF (1.58 ± 0.49 mL/min/g for group 1, 1.72 ± 0.46 mL/min/g for group 2, and 1.97 ± 0.32 mL/min/g for group 3; P = 0.14) and MFR (1.62 ± 0.57 for group 1, 1.90 ± 0.31 for group 2, and 2.27 ± 0.51 for group 3; P = 0.01) were lower in the non-obstructive and higher in the latent HCM group. LVOTGs demonstrated no significant correlation with any flow dynamics. In a multivariate regression analysis, maximal wall thickness was the only significant predictor for reduced peak MBF (β = -0.45, P = 0.003) and MFR (β = -0.63, P = 0.0001). Conclusion: Maximal wall thickness was identified as the strongest predictor of impaired dipyridamole-induced hyperemia and flow reserve in our study, whereas outflow tract obstruction was not an independent determinant.

KW - Hypertrophic cardiomyopathy

KW - Myocardial blood flow

KW - Outflow tract obstruction

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=84858602408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858602408&partnerID=8YFLogxK

U2 - 10.2967/jnumed.111.096156

DO - 10.2967/jnumed.111.096156

M3 - Article

VL - 53

SP - 407

EP - 414

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 3

ER -